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Abstract
Objective: Uncontrolled proliferation of health technologies (HT) is one contributor to the increasing pressure on
health systems to adopt new technologies. With limited resources, policy-makers encounter difficulties in fulfilling
their responsibility to meet the healthcare needs of the population. The aim of this study is to explore how policy-
makers’ reason about the diffusion and utilization of health technologies in Iran using magnetic resonance imaging
(MRI) and interferon beta as tracers.
Method: This qualitative exploration complements quantitative data generated in a research project investigating
the diffusion and utilization of MRI and interferon beta in Iran. Qualitative semi-structured interviews were
conducted with 13 informants in different positions and levels of authority in the Ministry of Health (MOH),
University of Medical Sciences, Health Insurance Organizations, and Parliament. The data was analysed using the
framework approach.
Findings: Although policy-makers appeared to be positive to health technology assessment (HTA), the processes
of policy-making described by the interviewees did not seem to be based on a full understanding of this
(discipline). Several obstacles to applying knowledge about HT and HTA were described. The current official plan
for MRI adoption and diffusion in the country was said not to be followed, and no such plan was described for
interferon beta. Instead, market forces such as advertising, and physician and consumer demand, appear to have
strong influence on HT diffusion and use. Dual practice may have increased the induced demand and also reduced
the supervision of the private sector by the MOH.
Conclusion: Management instability and lack of coordination in the MOH were found to be important obstacles to
accumulation of knowledge and experience which, in turn, could have led to suboptimal managerial and policy-
making processes. Furthermore marketing should be controlled in order to avoid creating unnecessary patient
demands and negative influences on physicians’ behavior.
Introduction and Aim
Health technologies (HT) are essential tools for addres-
sing health problems. They function as the backbone of
all health systems [1], regardless of the degree of sophis-
tication of the system. Health systems are under increas-
ing pressure to adopt new technologies due to rapid and
continuous innovation. The increasing number of emer-
g i n gH T ss e r v e st oi n t ensify both patients’ and
physicians’ demands. Levin and colleagues [2] argue that
open-ended introduction of HTs in health systems can
lead to unrealistic expectations and excessive demands.
Low- and middle-income countries (LMICs) face
increasing challenges due to incorporation, diffusion and
utilization of new and modern HTs. In a one-way flow
of HTs from high-income countries to LMICs, the rele-
vance of HTs to importing countries has often been
neglected in lieu of ‘newness’ of HTs [3]. It is suggested
that proliferation of HTs is a major contributor to rising
healthcare costs [4,5]. With limited resources, health
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fulfilling their responsibilities in meeting the health
needs of the population. Policy-makers therefore need a
systematic approach for efficient allocation of resources.
While the aim of health technology assessment (HTA)
is to provide scientific evidence to guide healthcare deci-
sions and policy-making [6], many LMICs, which are
now exposed to HT in the health market, lack govern-
ment and/or private organizations for HTA [7].
In our previous work, we have examined the diffusion
and utilization of two technologies–magnetic resonance
imaging (MRI) and interferon beta–considered to be
both sophisticated and costly in one middle-income
country, Iran [8-10]. These technologies have provided
new horizons in diagnostics and therapeutics, making
them captivating for many health systems. However,
they also provide examples of the challenges for most
low- and middle-income countries to afford new expen-
sive technologies with limited public resources. Mag-
netic resonance imaging (MRI) is a medical imaging
device used to visualize detailed internal structures of
the body. Because of MRI’s ability to make great con-
trast between the different tissues of the body, it is
widely used for diagnostic purposes especially in neuro-
logical and musculoskeletal imaging. MRI uses no ioniz-
ing radiation and imaging can be performed without
injecting contrast agents. It is a safe and highly effective
imaging technology. MRI was introduced in the late
1970s [11].
Interferon beta is a drug which is mainly used for
treatment of multiple sclerosis (MS). There are three
interferon beta products (Avonex, Rebif and Betaferon)
w h i c hh a v eb e e nu s e di nE u r o p ea n dt h eU So v e rt h e
past decade. It has been shown to be an effective drug
in reducing relapse rates in MS [12]. All three types of
interferon beta have been available in Iran since 1995.
Herceptin is a medicine for treating women with
breast cancer whose tumors are HER2 (Human Epider-
mal growth factor Receptor 2) positive [13]. HER2 status
determines how aggressive the breast cancer is and what
treatments are most likely to be effective [14]. Because
of the prognostic value of HER2 protein, testing for it,
performed on cancer cells removed during breast biopsy
or surgery, is becoming more common. To receive Her-
ceptin, the tumor must be tested and be HER2 positive
[14].
Findings from our earlier studies indicate that,
through unplanned diffusion, both MRI and interferon
beta have spread rapidly in Iran. Interferon beta has
b e e nf o u n dt ob eu s e da tl e v e l sh i g h e rt h a nt h o s ei n
some high-income countries [10].
In order to better clarify and understand these pre-
vious findings, we conducted an exploratory qualitative
study to investigate how policy-makers’ reason about
the diffusion and utilization of health technologies in
Iran using MRI and interferon beta as tracers.
Background
Study context
The Islamic Republic of Iran is a middle-income country
located in Southwest Asia, in the Middle East region.
Demographic, economic, and health indicators of Iran
are shown in Table 1.
Healthcare in Iran is provided by both a public (gov-
ernment) sector and a private sector, with health insur-
ance organizations (HIO) also involved in financing
healthcare provision. At the national level, the Ministry
of Health (MOH) is responsible for policy-making, plan-
ning, financing and supervision. On the provincial level,
medical universities have some responsibility for finan-
cing and planning. At the district level, urban and rural
health centers and district hospitals are executive units.
Although the importance of primary healthcare is
emphasized and financed by the MOH, the Ministry of
Health also has an important role in providing hospital
care. Secondary and tertiary healthcare is financed
through insurance schemes.
The situation in Iran is such that, in accordance with
the Iranian National Drug Policy [15], all pharmaceuti-
cals offered in the national market should meet quality
criteria satisfying international and national standards.
Only those drugs registered in the National Drug List
(NDL) are produced in, or imported to, Iran. Drugs on
this list are selected by the Iranian Drug Selecting Com-
mittee (IDSC), under the Food and Drug Department of
the MOH. Members of the IDSC rely on information
provided by the expert team of the IDSC secretariat
when determining whether or not to include a new for-
mula in the NDL [16].
On the other hand, medical devices and equipment
are the domain of the Directorate General of Medical
Equipment under the Deputy Minister for Health
Affairs. This directorate determines the need for procur-
ing equipment [17]. As noted by the WHO, while some
Table 1 Demographic, Economic and Health Worker
Indicators for Iran
Population (million) (2006)
a 70
GDP/capita (International $, 2004)
a 8367
Total expenditure on health as % of GDP (2005)
a 7.8
Total expenditure on health per capita (International $, 2005)
a 677
Life expectancy at birth, male/female (2005)
a 69/73
Physicians/10,000 inhabitants (2005)
a 9.0
Hospital beds/10,000 population (2005)
b 17.2
a: World Health Organization. Accessed January 2009. http://www.emro.who.
int/index.asp
b: World Health Organization. Accessed January 2009. http://www.who.int/en/
GDP, gross domestic product
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exist in Iran, others are said to be neglected or imma-
ture and are not linked to form a cohesive whole [17].
Methods
This qualitative explorative study complements other
data generated in a comprehensive multi-method, multi-
disciplinary research project investigating the diffusion
and utilization of HTs in Iran. In this study, semi-struc-
tured interviews were conducted with participants with
experience of national or provincial policy-making on
healthcare. This method is particularly appropriate when
quantitative research has been carried out and qualita-
tive data is required to clarify and illustrate the meaning
of findings [18].
Eighteen informants were purposefully [19] selected to
obtain a variation in professional roles and agency
affiliations in relation to HT. These individuals had
roles at the MOH, Universities of Medical Sciences
(UMS), the main HIOs and Parliament. After receiving
permission from the Ethics Committee of the University
of Medical Sciences of Kermanshah, Iran, potential
informants were contacted by telephone and asked to
suggest a time at which an interview could be con-
ducted. Ultimately, we were able to complete 13 inter-
views with informants in different positions and levels
of authority in the MOH, UMS, HIO, and Parliament as
shown in Table 2. One person declined participation in
the study; practical and logistic reasons prohibited the
participation of others.
Data Collection
The research team formulated an interview guide with
topics to be included in semi-structured interviews with
the interviewees. The interview guide was designed to
encourage the interviewees to describe their actual
experiences with HT in conversational form and to gen-
erate discussion of their perspectives on the topics
selected.
The first author (MP) conducted and audio-taped
interviews, after receiving written informed consent
from the 13 informants. The interviews began with an
open question to invite the respondents to relate their
recent experiences in decision-making related to HT.
Follow-up questions further probed areas of interest
raised in the course of conversation with the intervie-
wees. Use of MRI and interferon beta functioned as
examples of HT when probing during the interviews.
Topics addressed included views on: type of information
needed for decision-making, experiences of technology
dissemination in Iran including factors that facilitate
and obstruct dissemination, factors that might facilitate
or obstruct technology utilization, and policy needs
regarding technology dissemination and use.
The audio-taped interviews which were conducted in
Farsi lasted approximately 50 minutes and were later
transcribed verbatim by a professional transcriber and
checked for consistency with the recording by the first
author. The three team members who were fluent in
Farsi validated analyses of all interviews. For further dis-
cussion and validation, two transcripts were translated
into English to make them accessible to the members of
the research group who were not proficient in Farsi.
Finally, quotations selected from all interviews were
translated for the manuscript.
Data analysis
A framework approach [20,21] was used for analysis of
the interview texts. This approach was developed at the
National Centre for Social Research in England in the
1980s for use in applied qualitative research with clear
policy or clinical aims. This analytic method facilitates
linking qualitative and quantitative data [22].
The data was analyzed using the following stages of
framework analysis. To achieve general understanding,
the transcripts were read repeatedly by (MP) the first
author and (AE) the last author (familiarization with
data). In the next stage a thematic framework was
developed to function as the coding scheme (thematic
analysis). Based on existing literature and reviews of
the interviews, preliminary categories were developed.
The categories were then re-evaluated and rephrased
during the analytical process (Fig 1). Transcripts were
then coded (indexing) by (MP) the first author and
(AE) the last author. All codes derived from each tran-
script were transferred to a specific reference sheet
which contained the number of the transcript, page
number from which the code was drawn, and number
assigned to that specific code. In the next stage, chart-
ing, data was restructured by thematic content. In
order to allow tracking back to the interview source,
each theme, together with code related, was recorded
on a new sheet using the identifiers given above.
Charts were used to define and illustrate concepts and
experiences explicated by the participants (mapping
and interpretation).
Table 2 Number of interviewees selected, their position
and number of interviews conducted
Position No. of purposefully
selected interviewees
No. of interviews
conducted
Ministry of Health 8 7
University of
Medical Sciences
31
Health Insurance
Organization
44
Parliament 3 1
Total 18 13
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lics with the interview number shown in parentheses.
Information that might identify the policy-maker is
excluded, in an effort to ensure confidentiality.
Results
The major themes are presented in Fig. 1. These
themes, presented here separately for clarity, are interre-
lated, and consist of the following: information about
and importance of HTs; needs assessment; system man-
agement and coordination; adoption/diffusion of HTs;
utilization of HTs. The themes were addressed from var-
ious perspectives by the informants, for example with
regard to their own opinions, descriptions of praxis and,
to a lesser extent, regulations.
Information about and importance of HTs
Almost all interviewees pointed to the importance of
HTs and their utilization. They stated that HTs were a
means through which science and knowledge could be
implemented, whilst, at the same time, recognizing that
treatment of disease has become increasingly more com-
plex through the influence of HTs. One interviewee
explained that:
“Health technologies are of great importance when
physicians are unable to formulate a diagnosis based
on physical examination, for example, when an
affected organ does not have any pain receptors that
c o u l ds i g n a lt h ep a i n ,o rw h e nt h ea f f e c t e do r g a ni s
not directly accessible to physicians” (Int #7).
Several interviewees pointed out that HTs assist physi-
cians in providing their patients with sophisticated treat-
ment, with one interviewee explicitly emphasizing the
limitations a specialist would face without HTs, saying:
“A physician without health technology is like a soldier
without a gun” (Int #9).
Several interviewees argued that HTs reduce treatment
costs and that the ultimate costs of a system are also
decreased when applying new HTs such as innovative
surgical procedures, since they enable patients to
recover quickly and return to work. The potential role
of HTs for improving health was described by one of
the interviewees as follows:
“For the Third World countries, sometimes such pre-
liminary activities as plumbing works, sanitary ser-
vices or vaccination, which we know as primary
healthcare, leave much more impact than technolo-
gies of advanced healthcare on promotion of health
in society. This means that primary health care is a
priority for a country where the infant mortality rate
is three hundred out of one hundred thousand. But
when a country shows an infant mortality rate of less
than thirty, it means that this country has good
ANALYSIS 
Information on 
HTs 
Needs 
assessment 
Adoption/diffusion 
of HTs 
Utilization 
of HTs 
Information on 
and importance 
of HTs 
Needs 
assessment 
System 
management and 
coordination 
Adoption/ 
diffusion of 
HTs 
Utilization 
of HTs 
Figure 1 Description of the analytic process.
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reducing such a rate from thirty to fifteen, it needs to
use such other specialized services such as advanced
technology and drugs” (Int #10).
In contrast to the many positive comments, several
interviewees described HTs as not only as constructive,
but also potentially destructive if used in an uncon-
trolled manner: “health technologies could potentially be
harmful to public health. By consuming financial
resources health technologies will impede public health
promotion and preventive activities” (Int #13).
There was a high degree of consensus among intervie-
wees that importers or producers of HTs were their
main sources of information about HTs. For patients,
however, physicians were said to be the direct source of
information about HTs: “There is an information asym-
metry in the health market, people are not so informed
and physicians are those who produce the information”
(Int #5).
Interviewees argued that informing patients about
HTs could produce an increased demand for HTs. Dis-
seminating information was deemed important in the
sense that correct information could lead to appropriate
demand, but incorrect information could result in inap-
propriate demand. One interviewee said: “Inhabitants of
a very small district wanted to be provided with an MRI
machine; they thought that MRI is a therapeutic device”
(Int #3). This view was supported by an interviewee
from another agency who said: “When I go to rural
areas all people want me to provide them with doctors
and not other health workers” (Int #6).
Several interviewees clarified that data about HTs is
not systematically collected, processed and compiled.
They claimed that data is not usually used for proper
decision-making and allocation of resources. One of the
interviewees said that “unaware authorities would not be
able to inform people and manage technologies correctly”
(Int #13).
Needs assessment
Lack of needs assessment was considered by intervie-
wees from two dimensions. The first dimension was
whether any specific type of technology is needed in the
health system as articulated by “It is said that Herceptin
is not allowed to be imported into France but our mar-
k e ti so p e nt ot h a td r u ga n dw eu s ei te x c e s s i v e l y ” (Int
#4). Several interviewees stated that HTs are imported
into the country without any planning. They pointed
out that import of HTs is not usually based on needs
assessment and structured planning, resulting in a wide
variety of HTs in the health system. Several interviewees
pointed out that as inclusion of many HTs is not the
result of real needs assessment, they can cause problems
such as unnecessary use and increased treatment costs.
This view was articulated by one of the interviewees:
“There is a close relationship between MRI availability
in the private sector and increasing unnecessary use of
MRI for patients” (Int #11), while another said:
“We actually spend a lot of money for MS patients
but it should be noted that interferon beta is not the
only treatment that MS patients need. They may
also need rehabilitation, psychological and social
support” (Int #8).
Another interviewee pointed out the increasing
demand for importing MRIs, despite the charge for MRI
examinations remaining the same for the past four
years. This was seen to indicate that the tariff was high
enough to provide a substantial profit. Physicians were
also said to use HTs as soon as they are introduced,
without paying enough attention to needs assessment.
T h i s ,i nt u r n ,w a ss a i dt ol e a dt ot h eg e n e r a lp o p u l a -
tion’si n c r e a s i n ga w a r e n e s so fH T sa sap o t e n t i a lf o r
raising or inducing demand.
A second dimension raised concerning needs assess-
ment was the extent to which a technology should be
incorporated into the health system. As one interviewee
said: “...the number of MRI machines which had been
i n s t a l l e di nT e h r a np r o v i n c ew a se n o u g hf o rt h ew h o l e
population of the country” (Int #11). Several interviewees
stated that wealthier Western countries are able to use
very costly HTs like portable and mobile MRI machines,
but are then able to deliver services with fewer
machines, questioning why Iran does not adopt such a
policy.
One interviewee stated that performing needs analysis
in relation to newly introduced HTs is ignored especially
when similar technologies are already in use in the
health system. However, two interviewees from another
agency claimed that, in the case of pharmaceuticals,
HTs will not be imported into the country unless they
are more effective and less expensive than those already
in Iran’s pharmaceutical market. Several interviewees
emphasized that regardless of needs assessment, when
new technology is imported into the country, it easily
substitutes previous HTs.
One specific aspect of needs was addressed by an
interviewee who emphasized that HTs are needed for
medical students’ training even if their cost benefits are
not proven.
A few interviewees pointed to the scarcity of experts
and skillful persons for performing needs assessment
both in the MOH and HIOs. Training such experts to
perform needs analysis is a task which was seen as
important. Interviewees described different levels of pro-
ficiency available for different types of assessments.
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ple, two interviewees explicitly referred to all drugs
being assessed with regard to safety, quality and other
pharmacological and pharmacoeconomic aspects, with
needs assessment performed by expert committees.
While one of them stated needs assessment is based on
needs in the community and the burden of disease, the
other said: “we would not consider the number of
patients (when determining) whether or not the drug is
needed in Iran” (Int #10).
One interviewee claimed that, although health is a
multidisciplinary issue, the lack of attention to multidis-
ciplinary perspectives results in a lack of comprehensive-
ness in identifying needs and needs assessment. It was
also brought up that HT needs are judged in relation to
the level of health of the community, i.e. the higher the
level of health, the more advanced and sophisticated the
technology which is seen to be necessary. As one inter-
viewee said: “You know, I think that under some condi-
tions we can say that its role (HTs) is extensive, and
under some other conditions, we can say that its role is
not much. From my viewpoint, it depends on society”
(Int #10).
System management and coordination
Interviewees raised the lack of structured policy-making
in relation to HTs. Health system managers were
described as not getting involved in HT management.
Weakness in planning and policy-making was repeatedly
mentioned by interviewees. One interviewee stated that
“Less attention is paid to the importance of health man-
agement as a necessary expertise and skill for managing
the health system. There is a limited amount of research
on the health system and health policy in Iran” (Int #6).
Another interviewee supported this view, saying: “There
is a lack of a strong expert body in the Ministry of
Health for decision-making on health technologies” (Int
#5). One interviewee linked management to healthcare
costs and quality of care by saying: “We are not certain
that increasing healthcare costs, because of using health
technologies, has resulted in improving the quality of
care. It means that when we import technologies we need
to know how to manage them” (Int #2).
Weaknesses in applying management information sys-
tems to determine policy and allocation of resources,
coupled with lack of attention to non-medical evidence
(social and economic) were pointed to as contributing
to poor planning.
Another factor addressed was management instability,
which led to loss of accumulated experience. In an
unstable situation when policy-makers are frequently
changed, it would be difficult to make devised policies
sustainable, as stated by this interviewee: “...the Cabinet
is changed periodically every four years. Ministers and
other senior officials are replaced. This unstable execu-
tive situation is an impediment to the accumulation of
experience” (Int #7) and “when managers are dismissed
they take their experience with them” (Int #13). Such
management problems result in other health system
problems, as articulated by two interviewees from differ-
ent agencies: “We have enough financial resources, our
problem is in managing them which encounters us with
financial restrictions” (Int #4), and “lack of precise plan-
ning on how to apply health technology, causes financial
constraints in the Ministry of Health” (Int # 6).
According to one interviewee: “In developing countries,
although public opinion is not very strong and because of
weakness in governmental management, it is the market
which finally holds the dominant position” (Int #7). This
statement was supported by two other interviewees
from two other agencies, who said: “Under the pressure
of physicians and beneficiary demands, we have not had
alternatives other than changing our policies in relation
to health technologies” (Int #4), and “we knew that what
the community wanted was a false demand but, because
of their high pressure, we were not able to control it”
(Int #12).
Another issue raised related to detrimental effects of
physicians working simultaneously in public and private
sectors (dual practice). Some interviewees pointed to
lower salaries and income in the public sector compared
to the private sector as a major incentive for dual prac-
tice. Negative effects of dual practice which were
addressed included: a shift of patients from the public to
the private sector, facilitating induced demand, and
reducing the ability of government agencies to maintain
control, as stated by one interviewee: “The Ministry of
Health and Universities of Medical Sciences do not have
an efficient overview due to some public executive man-
agers practicing in the private sector” (Int #5).
Lack of coordination as an obstacle to HT manage-
ment was also addressed by interviewees, e.g. “Many
attempts were made to institute coordination in the
Ministry of Health but, unfortunately, all attempts
failed. Because each deputy in the Ministry of Health
considers himself to be in the position of authority, coor-
dination is a difficult task to be achieved” (Int # 6).
Another interviewee stated that “We have scattered
islands, each organization decides by itself; health insur-
ance by itself, the Medical Association by itself and the
Ministry of Health by itself” (Int #10). According to one
interviewee, the large number of HIOs also serves as an
obstacle to coordinating HT-related policies.
Adoption/diffusion of HTs
According to two interviewees, although the expert team
should assess each new drug from various perspectives
before including it in the NDL, pharmacoeconomic
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time consuming and complicated. As stated:
“The pharmacoeconomic committee does not assess
all drugs but only those drugs which are expensive or
that are claimed could be used for intractable dis-
eases” (Int # 10).
These interviewees stated that IDSC members are
usually pressured by drug importers and local manufac-
turers to include their formulas in the NDL. Intervie-
wees emphasized that one important criterion for
adopting pharmaceuticals is that they have already been
approved by agencies like the FDA and have European
or the US marketing permission.
Other interviewees clarified that the sovereign author-
ity for decision-making on HT financial coverage is the
Medical Services Insurance Supreme Council, composed
of representatives from different organizations, minis-
tries and major HIOs. This authority was said to make
coverage decisions based on information on cost-effec-
tiveness and cost-benefit analysis. One interviewee said
that “... to cover a service (HT), health insurance organi-
zations rely on cost-effectiveness rather than clinical
effectiveness, because a health insurance organization is
an economic corporation with limited resources and a
large number of beneficiaries” (Int #4).
Although the importance of conducting technology
assessment was emphasized, an interviewee from a dif-
ferent agency claimed that HIOs do not select appropri-
ate technologies because they do not perform such
assessments. The drawbacks of lacking HTA were
emphasized by an interviewee who said “we would not
pay enough attention to cost-effectiveness and cost-bene-
fits of health technologies, that’s why we are so passive
when adopting health technologies” (Int #8).
Several interviewees said that import of technologies
into the country and adoption without structured cri-
teria and control is increasing, as articulated by two
interviewees: “we noticed that suddenly the country has
become full of MRI” (Int #5); “it is said that Iran is the
second largest importer of new technologies among Mid-
dle-East countries” (Int #3). Lack of rules and regula-
tions; weak planning in relation to whether and to what
extent an HT should be imported or not; the large and
active private sector in the HT market and the inability
of the MOH to control the HT market, especially in the
private sector, all contribute to current problems
according to interviewees.
Despite many such statements, other views were also
expressed. One interviewee claimed that the need for
HTs, exemplified by MRIs, has been identified with
national distribution determined by the stratification
scheme, which is a structured plan for distribution of
health facilities, including HTs, throughout the country.
This scheme is based on provincial and district needs
estimated by the MOH.
The role of physicians in adoption and diffusion of
HTs was noted from several perspectives, as indicated
by statements such as: “Physicians always would like to
apply innovations for their likely curative effects on
patients” (Int #1), and “Physicians encourage and per-
suade district, provincial and national authorities to
adopt health technologies, in fact they want to use tech-
nologies wherever they are. That’s why they influence dif-
fusion of health technologies” (Int #13).
A factor often referred to by interviewees was the
influence on physicians of HT importer/manufacturer
advertising. One interviewee exemplified this by saying:
“Physicians are the most influential factor for adopting
health technologies. It is very likely that advertisements
by health technology producers stand behind them”
(Int #13).
Other factors mentioned as influencing decisions on
the adoption and diffusion of HTs included the eco-
n o m i cs i t u a t i o n ,s i z eo fp o p u l a t i o na n dc o v e r a g eb y
health insurance. Geographical inequities in HT distri-
bution were addressed both in relation to provincial
and regional levels. Differences in how readily HT
uptake occurred in different provinces was said to be
related to problems in health system performance in
relation to equity. One interviewee said that “One
important factor in technology adoption which makes
provinces different is the ability of their authorities and
politicians to obtain facilities from the government and
the Ministry of Health” (Int #12). This view, which
focused on the provincial level, can be contrasted with
another interviewee’s perspective, which focuses on
technology adoption at the regional level: “... another
influential factor is the intention of authorities of the
country who want to develop their country and make it
famous by adopting sophisticated and advanced tech-
nologies to attract patients from neighboring countries”
(Int #13)
Utilization of HTs
Most interviewees said that HT utilization is increasing
in the country, although without regulation by a specific
plan or guidelines. Inappropriate use of technologies
was said by these interviewees to be a major problem in
Iran.
As noted above, this was often related to the behavior
of physicians. A wide range of other contributors to the
unnecessary use of HTs was also described, including
uncontrolled importation of HTs, high tariffs, lack of
guidelines, and the use of HT to increase profits. The
important potential role that guidelines could play for
appropriate use of HTs was also emphasized.
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amount of interferon beta is used in Iran, with use
increasing in recent years. Two interviewees stated that
this use is not proportional to the expected increase in
MS patients as there has been a 10-fold increase in
interferon beta use over the past six years. As is the
case with other HTs, one interviewee related the
increasing use of interferon beta to advertising by phar-
maceutical companies. Another reason described was
physicians’ practice, as some rely on MRI results rather
than clinical findings. This was said to lead to inap-
propriate use of interferon beta. Other factors for
increased interferon beta use mentioned by interviewees
were the increasing number of MS patients, incremental
consumption of the drug even in cases without indica-
tion, and government subsidies making it affordable for
more MS patients. One interviewee said that: “During
the last one-two years, we attempted to adjust the sub-
sidy of this drug because we believe that this drug is not
really useful for the patients in most of the cases. For
some patients, however, it has been useful” (Int #10).
Prescribing drugs without adequate indication is pro-
blematic, as stated by an interviewee: “Herceptin is sup-
posed to be used only by those patients who are receptor
positive. Although most of our clinical laboratories can-
not technically detect the receptor, physicians prescribe
this drug to many patients” (Int #4).
Discussion
Although policy-makers appeared to be positive to
Health Technology Assessment (HTA), the processes of
policy-making described by the interviewees did not
seem to be based on a full understanding of this (disci-
pline). Several obstacles to applying knowledge on HT
and HTA were described. The current official plan for
MRI adoption and diffusion in the country was said not
to be followed, and no such plan was described for
interferon-beta. Instead, market forces such as advertis-
ing, and physician and consumer demand, appear to
have strong influences on HT diffusion and use.
These findings were made possible through the use of
semi-structured interviews, analyzed using framework
analysis, to better understand policy related issues of
health technology in a middle-income country. Health
technology and its assessment, despite its history in
Western countries, is a new field of research in some
middle-income countries [23]. At the same time qualita-
tive research approaches are still considered innovative
in this field. Strengths of this study include it being
designed to provide answers to questions which
emerged from empirical quantitative studies conducted
by the same researchers. Combining different areas of
expertise in healthcare, health policy and research
allowed the research team to investigate these issues
comprehensively [24]. Although the sample is a limited
one, and a wider range of perspectives might have
added additional information, this data is unique and
provides considerable insight into policy-makers’ per-
spectives of the factors obstructing the development of
systematic HTA decision-making in Iran.
It has been suggested that “policy develops through
evolution rather than revolution and the wise policy-
maker makes incremental changes to reduce uncertainty
and avoid mistakes” [25]. Furthermore, HTA has been
pointed out as a form of research to support the process
of policy-making in healthcare by providing reliable
information, which can be utilized in formulating and
addressing problems [26,27]. Thus, it is important to
understand why evidence is not readily transferred into
practice in the policy-making process. However, as
Black [28] argues, to be influential in the policy-making
process, research should target the values of policy-
makers.
One finding was that needs assessment was not a well
established process in procuring HTs. Furthermore,
scarcity of trained and skillful experts was described as
one obstacle to performing needs assessment. Policy-
makers need context-specific input to fit the particular
purpose [25]. Obviously, one requirement for producing
such input is trained and skillful staff. Hivon et al. [29]
argue that there are three major limitations to the use
of HTA–organizational, material and scientific. The
absence of skilled staff with good knowledge and under-
standing of HTA is a scientific limitation which makes
it difficult to produce context-specific input.
Lack of coordination at the policy-making level of the
healthcare system was also found to be problematic.
Coordination is generally acknowledged to be an impor-
tant factor for increasing organizational effectiveness,
defined here as a measure of the extent to which a pro-
gram or sector is successful in achieving its predeter-
mined goals and objectives [30]. Based on this data, the
question of who should coordinate who arises and how
such coordination is best accomplished. An increase in
the number of departments and organizations involved
in HT risks leading to escalating complexity and confu-
sion [30], as does involvement of various deputies and
departments not only within the MOH but also between
the MOH and other organizations such as HIOs. This
leads to a wide range of players with different interests
and powers, making coordination within and between
them difficult.
Another striking finding is the presence of dual prac-
tice by physicians in both the public and private sectors,
which was described by interviewees as a common pat-
t e r n .T h i si sv e r yc o m m o ni nm a n yL M I C s[ 3 1 ] .G o v -
ernmental permission for dual practice by physicians is
a heavily debated issue. Ferrinho et al. [32], argue that
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Page 8 of 10dual practice could result in “predatory behavior” i.e.
practitioners prefer their self-gain instead of the legiti-
mate interests of their colleagues or patients. This kind
of behavior could lead to generating increasing demand
for treatment which in turn would profoundly influence
HT utilization. Different potential strategies for limiting
dual practice in the public and private sectors utilized in
other settings might also be helpful in Iran, e.g. limiting
the quantity of services that physicians can perform in
the private sector, limiting the income that they can
earn from the private sector and raising public salaries
[31]. Each strategy selected would need to be implemen-
ted consistently to prevent negative consequences of
dual practice.
Advertisements by importers and manufacturers of
HTs was stated to be an influential factor in relation to
adoption and use of HTs in Iran. This is not specific to
this setting. Mansfield et al. [33] for example, used
Vioxx as an example of how marketing was well beyond
science. They also refer to other problems with advertis-
ing by exemplifying how marketing of hormone-replace-
ment therapy for preventing cardiovascular disease
convinced physicians to use these drugs prior to com-
pletion of any clinical trials. In our data, both of these
phenomena are present with regard to dissemination
and use of MRIs and interferon beta as marketing goes
beyond the scientific indications and is said to increase
physician and consumer demand. It has also been
argued that contexts in which market values dominate
leave little room for morality and sound values [34].
The situation described for Iran i.e. having problems
with dual practice, the lack of needs assessments, and,
in a wider scope, having problems in relation to selec-
tion, distribution and use of HTs is also true for some
high-income countries [35-38]. Implementing effective
policies in these areas remains a challenge.
Policy implications
A strategic plan, based on needs assessment and priority
setting in relation to HT and HTA, is suggested to be
determined by the highest authorities of the MOH. An
MOH-led overview could lead to the formation of a
national coordination body or formulation of a strategic
national plan for HT. The presence of a national coordi-
nation body could assist the development, implementa-
tion, monitoring and evaluation of HT policies and
action plans [39]. In many LMICs, even when there are
regulations in place, they are not followed strictly [32,40].
It should be emphasized that a national coordination
body should not just be a technical advisory section, but
should have a mandate to examine compliance with offi-
cial policy and obstacles to policy implementation.
Recent attempts, such as establishing a health reform
unit in the MOH, greater orientation towards health
system research in universities, development of research
in the field of HTA, increasing participation of Iranian
researchers in international conferences concerning HT
and its assessment and the presence of a ‘Health and
Treatment Commission’ in the Parliament which is able
to provide legislative and financial support, all could con-
tribute to make the suggestions above practical.
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